Eucrates Biomedical Acquisition Corp.
EUCR
NASDAQ Capital Market10.04
USD
- -
- -
CIK
0001822929
ISIN
VGG3141W1068
CUSIP
G3141W106
Return %
Stock
S&P500
1Y
1.62
18.21
3Y
0.40
64.38
5Y
0.40
72.43
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Parag Phoolchand Saxena MBA, MS
- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- 250 West 55th Street New York City NY United States of America 10019
- IPO Date
- Dec 28, 2020
- CIK
- 0001822929
- Similar Companies
- Business
- Eucrates Biomedical Acquisition Corp. (Nasdaq: EUCR) operates as a blank check company, or special purpose acquisition company (SPAC), formed to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses, primarily targeting the biomedical and healthcare industries. The company focuses on North American and European healthcare companies with potential for transformational change through the convergence of biomedicine and data science; it offers no current operational products or services beyond its SPAC structure, which includes ordinary shares and redeemable warrants exercisable at $11.50 per share. Founded in 2020 and headquartered at 250 West 55th Street, Suite 13D, New York, New York, the company raised $100 million in its initial public offering in October 2020, with units listed under EUCRU, ordinary shares under EUCR, and warrants under EUCRW. In a significant development, Eucrates Biomedical Acquisition Corp. announced its liquidation in April 2023 after failing to consummate an initial business combination within the required timeframe under its Amended and Restated Memorandum and Articles of Association; it redeemed all public shares at approximately $10.00 per share, liquidated its trust account, delisted from Nasdaq via Form 25, and terminated SEC registration via Form 15, rendering the entity defunct as of April 27, 2023. No subsidiaries, parent companies, or subsequent operational activities are reported following the dissolution.